Brief

On March 21, 2025, the National Health Surveillance Agency (Anvisa) issued an update regarding RPBR: Check out the list of active ingredients that will be evaluated in 2025. The update includes information on the periodicity and requirements for the submission of Relatórios Periódicos de Avaliação Benefício-Risco (RPBR), a document outlining the evaluation of the benefit-risk profile of registered medicines, as mandated by RDC nº 406/2020 and IN nº 63/2020.

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies